| OBSERVATION'S |
Many companies have been similarly hit by product withdrawals. For example, at about this time last year, two drugs for which Co had been supplying synthetic reagents failed after launch. "It was painful. We had nothing to fill the gap. "But this time, we're coming back a bit because of new projects involving statin drugs." For example, Co is known as a supplier of organolithiums. Now, the company is extending that knowledge to other organometallics or other reagents made from organolithiums. And it is pursuing opportunities to prepare intermediates through syntheses involving organometallics as reagents. "We have been trying to set a new image by calling ourselves 'more than lithium.' We want to emphasize that we're staying with our lithium roots but stepping beyond to manufacture other reagents and to do organic synthesis."
|